Objective To evaluate the efficacy and adverse events of irinotecan (CPT-11)combined with PF in the treatmentof patients with advanced esophageal cancer. Methods A totalof 73 cases with advanced esophageal entered this trial. The patientswere randomly divided into trial group and control group, and 37 cases received chemotherapy of PIF regimen. 36 cases received chemotherapy of PF regimen. Each patient received at least 2 cyclesof chemotherapy. Results The efficacy and adverse events were evaluated in all patients. The overall response ratewas 59.46% in the PIF group and 46. 67% in the PF group, the difference between the two groups did not reach statistical significance(P ＞ 0. 05). The median time to progression(TTP)was 5.9 months in the PIF group and 4.4 months in the PF group. Themedian survival time(MST) was 12. 2months in the IP group and 9.3 months in the PF group. The main adverse events included elosuppression, nausea, vomiting and diarrhea. A lone diarrheawith statistically significant difference detected(P＜ 0. 05). Conclusion For advanced esophageal cancerpatients, PIF treatment achieves better therapeutic effects than PF treatment. it is toxicity is tolerable, It is valuable for clinical practicing.